Navigating metabolic pathways to enhance antitumour immunity and immunotherapy
X Li, M Wenes, P Romero, SCC Huang… - Nature reviews Clinical …, 2019 - nature.com
The development of immunotherapies over the past decade has resulted in a paradigm shift
in the treatment of cancer. However, the majority of patients do not benefit from …
in the treatment of cancer. However, the majority of patients do not benefit from …
Metabolic drivers of invasion in glioblastoma
Glioblastoma is a primary malignant brain tumor with a median survival under 2 years. The
poor prognosis glioblastoma caries is largely due to cellular invasion, which enables escape …
poor prognosis glioblastoma caries is largely due to cellular invasion, which enables escape …
Pharmacotherapeutic treatment of glioblastoma: where are we to date?
L Gatto, V Di Nunno, E Franceschi, A Tosoni… - Drugs, 2022 - Springer
The clinical management of glioblastoma (GBM) is still bereft of treatments able to
significantly improve the poor prognosis of the disease. Despite the extreme clinical need for …
significantly improve the poor prognosis of the disease. Despite the extreme clinical need for …
The versatile role of HuR in Glioblastoma and its potential as a therapeutic target for a multi-pronged attack
Glioblastoma (GBM) is a malignant and aggressive brain tumor with a median survival of∼
15 months. Resistance to treatment arises from the extensive cellular and molecular …
15 months. Resistance to treatment arises from the extensive cellular and molecular …
CAR T Cells
T Tudor, ZA Binder… - Neurosurgery Clinics, 2021 - neurosurgery.theclinics.com
Glioblastoma (GBM), the most common primary malignant brain tumor in adults, is
associated with extremely poor survival outcomes and is a universally fatal disease. 1 …
associated with extremely poor survival outcomes and is a universally fatal disease. 1 …
Potential mechanisms of human recombinant arginase I (Co)-PEG5000 [HuArgI (CO)-PRG5000] induced cytotoxicity in glioblastoma cells.(c2018)
Y El Jawhari - 2018 - laur.lau.edu.lb
Glioblastoma multiforme (GBM) is a highly aggressive glioma arising in the central nervous
system accounting for more than 70% of all brain tumors. Due to the resistance and …
system accounting for more than 70% of all brain tumors. Due to the resistance and …
[引用][C] Short-term, low concentration of Temozolomide modulates proteins associated with glucose and amino acid metabolism and antigen processing and …
P NARAYANAN - bridges.monash.edu
Glioblastoma is the most aggressive and invasive form of brain tumour. More than half of the
patients with glioblastoma develop resistance to chemotherapy. This study discovers …
patients with glioblastoma develop resistance to chemotherapy. This study discovers …